TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32858229

Group type: EXPERIMENTAL
Intervention: Treadmill training with virtual reality
Number of subjects: 144

Group type: COMPARATOR
Intervention: Treadmill training alone
Number of subjects: 144
Study: 33398056

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Penta 1 vaccination
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Penta 3 vaccination
Number of subjects: 986
Study: 32994178

Group type: EXPERIMENTAL
Intervention: Electromagnetic method
Number of subjects: 52

Group type: COMPARATOR
Intervention: Blind method
Number of subjects: 52
Study: 36061400

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine‐propofol (sketofol) group
Number of subjects: 66

Group type: COMPARATOR
Intervention: General anesthesia (control group)
Number of subjects: 66
Study: 33411341

Group type: EXPERIMENTAL
Intervention: Mentor-implemented violence prevention program (Take Charge!)
Number of subjects: 98
Study: 32437569

Group type: EXPERIMENTAL
Intervention: Highest tertile of physical activity (PA)
Number of subjects: 3050
Study: 35599183

Group type: EXPERIMENTAL
Intervention: mTESE
Number of subjects: 100

Group type: COMPARATOR
Intervention: multiple needle‐pass TESA
Number of subjects: 100

Group type: COMPARATOR
Intervention: multiple needle‐pass TESA + salvage mTESE
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: mTESE and multiple needle‐pass TESA
Number of subjects: 100
Study: 34289996

Group type: EXPERIMENTAL
Intervention: ASyMS (intervention; n=415)
Number of subjects: 829

Group type: COMPARATOR
Intervention: Standard care (control; n=414)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: ASyMS
Number of subjects: 829
Study: 32107359

Group type: EXPERIMENTAL
Intervention: Postoperative pain scores on POD1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Postoperative pain scores on POD2
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Unacceptable pain (NRS ≥ 6) on POD1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Unacceptable pain (NRS ≥ 6) on POD2
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Unacceptable pain (NRS ≥ 6) on POD2 as a predictor
Number of subjects: 160
Study: 36208097

Group type: EXPERIMENTAL
Intervention: 5-day azacitidine (AZA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: 7-day azacitidine (AZA)
Number of subjects: 55
Study: 33040598

Group type: EXPERIMENTAL
Intervention: Integrated programme (a pre-admission day, two weeks at home, two weeks inpatient followed by home-based activities, plus two 2-day inpatient booster sessions, and six-month follow-up visit)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Existing programme (four-week inpatient, and six-month follow-up visit)
Number of subjects: 165
Study: 32203980

Group type: EXPERIMENTAL
Intervention: Deferasirox dispersible tablets (10 to 40 mg/kg per day)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 225
Study: 34105208

Group type: EXPERIMENTAL
Intervention: Exclusive e‐cigarette users
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Dual users
Number of subjects: 114

Group type: COMPARATOR
Intervention: Exclusive smokers
Number of subjects: 114
Study: 32798567

Group type: EXPERIMENTAL
Intervention: High early parenteral soybean oil lipid intake starting at 2 g/kg per day, increasing to 3 g/kg per day the following day.
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group started at 0.5-1 g/kg per day, increasing daily by 0.5-1 g/kg per day till reaching 3 g/kg per day.
Number of subjects: 83
Study: 34319571

Group type: EXPERIMENTAL
Intervention: Greater sleep disturbance
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Discrimination
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Psychosocial stressors
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Good sleep
Number of subjects: 302
Study: 32060825

Group type: EXPERIMENTAL
Intervention: Raw Pongamia pinnata shells (NPP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phosphoric acid-activated Pongamia pinnata shells (PPP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulphuric acid-activated Pongamia pinnata shells (SPP)
Number of subjects: 0
Study: 34255087

Group type: EXPERIMENTAL
Intervention: Organizationally tailored approach
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard approach (core components only)
Number of subjects: 14
Study: 34220819

Group type: EXPERIMENTAL
Intervention: Prevenar13® (PCV13)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Haemophilus influenzae‐type b (Hib) vaccine
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Combined effects of PCV13
Number of subjects: 225
Study: 36273160

Group type: EXPERIMENTAL
Intervention: 1:100 PI diluted sitz bath
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: 1:200 PI diluted sitz bath
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: 1:300 PI diluted sitz bath
Number of subjects: 268

Group type: COMPARATOR
Intervention: Perianal cleaning care
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 268
Study: 34679101

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (resistance and aerobic exercises, 3 times per week for 6 months)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual care (standard care)
Number of subjects: 101
Study: 34855329

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 1077
Study: 34899398

Group type: EXPERIMENTAL
Intervention: 3-month interactive behavioral modification intervention (INT) with guided text message feedback (GTF)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Long-term feedback group (LT-GTF) continuing GTF for another nine months
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Short-term feedback group (ST-GTF) that stopped receiving GTF
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-directive wellness education control (CON)
Number of subjects: 56
Study: 33227803

Group type: EXPERIMENTAL
Intervention: Daily probiotic milk (once daily)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Triweekly probiotic milk (3 days a week)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo milk (without probiotics)
Number of subjects: 487
Study: 36447243

Group type: EXPERIMENTAL
Intervention: High-dose ECV19 (20 μg RBD)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Low-dose ECV19 (10 μg RBD)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 34948597

Group type: EXPERIMENTAL
Intervention: Images containing vapor and/or a device or e‐liquid
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Images from warning labels
Number of subjects: 200
Study: 32353544

Group type: EXPERIMENTAL
Intervention: BUP-XR
Number of subjects: 300

Group type: COMPARATOR
Intervention: BUP-SL
Number of subjects: 300
Study: 35449351

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-led stewardship program for appropriate use of acid suppression therapy
Number of subjects: 197
Study: 32242396

Group type: EXPERIMENTAL
Intervention: Lingqi Huangban granule (LQHB) plus intravitreal ranibizumab (IVR) injections
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravitreal ranibizumab (IVR) injections
Number of subjects: 60
Study: 34504129

Group type: EXPERIMENTAL
Intervention: Neuromodulation with alternating currents stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with optic nerve damage before treatment
Number of subjects: 0
Study: 32534080

Group type: EXPERIMENTAL
Intervention: Rapidly absorbable polyglactin 910 (Vicryl Rapide)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Nylon (Ethilon)
Number of subjects: 105
Study: 36327345

Group type: EXPERIMENTAL
Intervention: Computer based cognitive therapy (CBCT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CBCT + Mediterranean equivalent diet (MED)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CBCT + MED + Exercise regime
Number of subjects: 60

Group type: COMPARATOR
Intervention: Health awareness instructions (Control)
Number of subjects: 60
Study: 33233717

Group type: EXPERIMENTAL
Intervention: Blended cognitive-behavioral intervention (integrating face-to-face sessions with a web-based program)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blended cognitive-behavioral intervention
Number of subjects: 0
Study: 36091012

Group type: EXPERIMENTAL
Intervention: Mepolizumab (300 mg, subcutaneous, every 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34698726

Group type: EXPERIMENTAL
Intervention: Short antibiotic prophylaxis (24 hours)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Extended antibiotic prophylaxis (7 days)
Number of subjects: 85
Study: 32024741

Group type: COMPARATOR
Intervention: Education in Amharic
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Education in English
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups (Amharic and English)
Number of subjects: 84
Study: 36330836

Group type: EXPERIMENTAL
Intervention: Imagery cognitive bias modification (imagery CBM)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control arm (four weeks of weekly questionnaires)
Number of subjects: 188
Study: 34391232

Group type: EXPERIMENTAL
Intervention: GT100Hz
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: GT2Hz
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: GI4KHz/100Hz
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: GI2KHz/100Hz
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: GI4KHz/2Hz
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: GI2KHz/2Hz
Number of subjects: 280

Group type: COMPARATOR
Intervention: GIP (placebo interferential group)
Number of subjects: 280

Group type: COMPARATOR
Intervention: GTP (placebo TENS group)
Number of subjects: 280
Study: 32384147

Group type: EXPERIMENTAL
Intervention: Arginine therapy (100 mg/kg IV 3 times/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Arginine therapy (loading dose 200 mg/kg then 100 mg/kg TID)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Arginine therapy (loading dose 200 mg/kg followed by continuous infusion 300 mg/kg per day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Arginine therapy (all doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (steady-state cohort)
Number of subjects: 12
Study: 35997833

Group type: EXPERIMENTAL
Intervention: Leucocyte‐poor platelet‐rich plasma (LP‐PRP) + hyaluronic acid (HA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Autologous microfragmented adipose tissue (AMAT)
Number of subjects: 50
Study: 34797272

Group type: EXPERIMENTAL
Intervention: Yoga-based cognitive behavioral therapy (Y-CBT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 58
Study: 33283717

Group type: EXPERIMENTAL
Intervention: AML group (patients with acute myeloid leukemia)
Number of subjects: 30
Study: 36369984

Group type: EXPERIMENTAL
Intervention: Bursectomy
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Omentectomy alone
Number of subjects: 1204
Study: 33164936

Group type: EXPERIMENTAL
Intervention: Vitamin D 800 IU/day
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo (matching starch granules)
Number of subjects: 183
Study: 35537465

Group type: EXPERIMENTAL
Intervention: Alcohol (BrAC = .10%)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (no alcohol)
Number of subjects: 94
Study: 34474163

Group type: EXPERIMENTAL
Intervention: Elafin
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Combination of ST2 and REG3α
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Elafin combined with ST2 and REG3α
Number of subjects: 526
Study: 35698203

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) group - loading dose of 1 μg/kg for 15 min and continuous infusion at 0.6 μg/kg/h until 30 min before the end of operation.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group - normal saline infusion.
Number of subjects: 120
Study: 33256794

Group type: EXPERIMENTAL
Intervention: GlideScope™ visualization
Number of subjects: 86

Group type: COMPARATOR
Intervention: Neck flexion with lateral neck pressure
Number of subjects: 86
Study: 34030163

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study: 33676504

Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening decision aid (DA) prototype
Number of subjects: 27
Study: 35162346

Group type: EXPERIMENTAL
Intervention: 4 mL of plain 0.5% ropivacaine with perineurally added 1 mL/4 mg of dexamethasone (Group I)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 4 mL of plain 0.5% ropivacaine with perineurally added 1 mL of 0.9% saline (Group II)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 4 mL of plain 0.5% bupivacaine with perineurally added 1 mL of 0.9% saline (Group III)
Number of subjects: 45
Study: 33446115

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) + 2 nucleos(t)ides (NRTIs)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 707
Study: 32745830

Group type: EXPERIMENTAL
Intervention: mindfulness+values
Number of subjects: 206

Group type: COMPARATOR
Intervention: values only
Number of subjects: 206
Study: 35934082

Group type: EXPERIMENTAL
Intervention: REGN1908/1909 600 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 33933340

Group type: EXPERIMENTAL
Intervention: Data completeness assessment
Number of subjects: 1839

Group type: EXPERIMENTAL
Intervention: Data accuracy assessment
Number of subjects: 1839

Group type: EXPERIMENTAL
Intervention: Data verification
Number of subjects: 1839

Group type: COMPARATOR
Intervention: Correlation analysis
Number of subjects: 1839
Study: 33588513

Group type: EXPERIMENTAL
Intervention: Directional microphone with noise reduction on
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Directional microphone with noise reduction off
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Omnidirectional microphone with noise reduction on
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Omnidirectional microphone with noise reduction off
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Working memory capacity (WMC) group
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tolerable time estimates
Number of subjects: 19
Study: 34935603

Group type: EXPERIMENTAL
Intervention: VR training along with conventional physical therapy (CPT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: FES for Rectus Abdominis and Erector Spinae with CPT
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (FES + CPT)
Number of subjects: 18
Study: 33661437

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 989
Study: 32455947

Group type: EXPERIMENTAL
Intervention: Dietary intervention (12-week weight loss program)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (Q1, no significant weight loss)
Number of subjects: 137
Study: 36008108

Group type: EXPERIMENTAL
Intervention: Vitamin D treatment (50,000 IU bi-weekly)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 34798706

Group type: EXPERIMENTAL
Intervention: QLB-LSAL with 0.5% ropivacaine (25 mL)
Number of subjects: 106

Group type: COMPARATOR
Intervention: TQLB with 0.5% ropivacaine (25 mL)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 106
Study: 36064382

Group type: EXPERIMENTAL
Intervention: Chitosan supplementation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 64
Study: 34486986

Group type: EXPERIMENTAL
Intervention: Istradefylline 20 mg/day
Number of subjects: 3245

Group type: EXPERIMENTAL
Intervention: Istradefylline 40 mg/day
Number of subjects: 3245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3245

Group type: EXPERIMENTAL
Intervention: Istradefylline (both dosages)
Number of subjects: 3245
Study: 36651339

Group type: EXPERIMENTAL
Intervention: PF‐AES
Number of subjects: 302

Group type: COMPARATOR
Intervention: PP‐ZES
Number of subjects: 302
Study: 33831611

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Microsurgical treatment (MST)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 74
Study: 32084522

Group type: EXPERIMENTAL
Intervention: High-dose spatially fractionated radiation therapy (12 to 14 Gy via dose cylinders)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard treatment (external beam radiation therapy to the entire prostate and proximal seminal vesicles to 76 Gy at 2 Gy/fraction)
Number of subjects: 25
Study: 32571103

Group type: EXPERIMENTAL
Intervention: Brisbane Evidence-Based Language Test
Number of subjects: 0
Study: 34802471

Group type: COMPARATOR
Intervention: Brief BP counseling and an educational brochure
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitor (HBPM) with a mailed report of their home readings
Number of subjects: 100
Study: 34256607

Group type: EXPERIMENTAL
Intervention: Gabapentin (1,200 mg/day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 34460904

Group type: EXPERIMENTAL
Intervention: Antibiotic Stewardship Rounds (ASRs)
Number of subjects: 4683

Group type: COMPARATOR
Intervention: Control group (no ASRs)
Number of subjects: 4683
Study: 34033975

Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy (platinum and pemetrexed)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Chemotherapy alone (platinum and pemetrexed)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy
Number of subjects: 332

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 332
Study: 35653758

Group type: EXPERIMENTAL
Intervention: Hearing emotion labels before sorting (e.g., 'happy faces go here')
Number of subjects: 128

Group type: COMPARATOR
Intervention: Not given labels (e.g., 'faces like this go here')
Number of subjects: 128
Study: 35396587

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) and cetuximab (Cet)
Number of subjects: 218
Study: 33536102

Group type: EXPERIMENTAL
Intervention: Simvastatin (10-20 mg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Captopril (0.2 mg/kg/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: L-carnitine (50 mg/kg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 100
Study: 32114933

Group type: EXPERIMENTAL
Intervention: WiiNWalk (experimental group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Attention control (control group)
Number of subjects: 64
Study: 35714357

Group type: EXPERIMENTAL
Intervention: Preoperative TEAS (group E1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intraoperative TEAS (group E2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 90
Study: 32196462

Group type: EXPERIMENTAL
Intervention: mHealth positive psychology program intervention group
Number of subjects: 654

Group type: COMPARATOR
Intervention: Relevant online mental health information control group
Number of subjects: 654
Study: 35833600

Group type: EXPERIMENTAL
Intervention: Weight self-awareness plan (WAP)
Number of subjects: 279
Study: 33894422

Group type: EXPERIMENTAL
Intervention: Three-quarter view stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Front view stimuli
Number of subjects: 0
Study: 32339664

Group type: EXPERIMENTAL
Intervention: verum-tDCS
Number of subjects: 24

Group type: COMPARATOR
Intervention: sham-tDCS
Number of subjects: 24
Study: 35037116

Group type: EXPERIMENTAL
Intervention: Berberine (900 mg/day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 32321451

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 33540038

Group type: EXPERIMENTAL
Intervention: Exercise group (a structured multicomponent exercise program comprised of aerobic and resistance training as well as impact loading)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 115
Study: 32746774

Group type: EXPERIMENTAL
Intervention: 200g of cod twice a week for 16 weeks
Number of subjects: 137

Group type: COMPARATOR
Intervention: Standard diet (control group)
Number of subjects: 137
Study: 36416197

Group type: EXPERIMENTAL
Intervention: Targeted advertising on Facebook
Number of subjects: 282
Study: 33880558

Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
Number of subjects: 1274

Group type: COMPARATOR
Intervention: Dolutegravir/abacavir/lamivudine (DTG/ABC/3TC)
Number of subjects: 1274

Group type: COMPARATOR
Intervention: Dolutegravir + emtricitabine/tenofovir alafenamide (DTG+F/TAF)
Number of subjects: 1274
Study: 33253318

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (2x/week for 6 months)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Baseline visceral-to-subcutaneous fat ratio (VFR)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Loss of muscle mass
Number of subjects: 65
Study: 35404227

Group type: EXPERIMENTAL
Intervention: Propranolol administered orally 60 to 75 minutes prior to psychotherapeutic sessions
Number of subjects: 0
Study: 34472211

Group type: EXPERIMENTAL
Intervention: Gut microbial synthesis of the SCFA butyrate
Number of subjects: 482
Study: 32748579

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (NMB) group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Moderate neuromuscular block (NMB) group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (Deep and Moderate NMB)
Number of subjects: 100
Study: 34618513

Group type: EXPERIMENTAL
Intervention: Therapists' self-perceived alliance-fostering effectiveness
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral orientation
Number of subjects: 212
Study: 33831625

Group type: COMPARATOR
Intervention: Surgical dressing changed twice a week (HMO)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Surgical dressing untouched until first follow up (SDU)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Surgical dressing removed at first postoperative day (SDR)
Number of subjects: 84